CRS 2022 (v22.0 and v22.1)

CRS VERSION 22.1

CRS Version 22.1 was released on July 8, 2022.

View the CRS 2022 (v22.1) National GPRA/GPRAMA Report Performance Measure List and Definitions [PDF - 685 KB]

View the CRS 2022 (v22.1) National GPRA Developmental Report Performance Measure List and Definitions [PDF - 767 KB]

Key enhancements included in CRS Version 22.1 are shown below.

Logic Changes to National GPRA/GPRAMA Report Measures
- GPRA Developmental Measures:
  - Added the following GPRA Developmental topic:
    - Screening, Brief Intervention, and Referral to Treatment (SBIRT)
  - Removed the following GPRA Developmental topic:
    - Cancer Screening: Pap Smear Rates
  - Added measures to and removed measures from Adult Immunizations topic to align with new Pneumococcal recommendations.
  - Updated codes and/or logic in the following measures: Weight Assessment and Counseling for Nutrition and Physical Activity; Appropriate Medication Therapy after a Heart Attack; HIV Quality of Care; Chlamydia Testing; Proportion of Days Covered by Medication Therapy; Concurrent Use of Opioids and Benzodiazepine
- Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes: (1) Removed lower age limit for patients with ASCVD. (2) Changed lower age limit to 20 for patients with LDL greater than or equal to (>=) 190. (3) Changed the time period for the denominator exclusion of rhabdomyolysis to be during the report period. (4) Updated the statin allergy denominator exception to statin-associated muscle symptoms or an allergy. (5) Removed the denominator exception for patients with LDL less than (<) 70. (6) Updated medication taxonomy BGP PQA STATIN MEDS.
- Diabetes: Nephropathy Assessment: Added LOINC codes 98979-8, 98980-6 to BGP ESTIMATED GFR LOINC taxonomy.
- Adult Immunizations: Added CVX codes 215, 216 and CPT codes 90671, 90677 to PCV13 definition.
- Cancer Screening: Pap Smear Rates: (1) Changed topic name to Cervical Cancer Screening. (2) Added HPV Primary only in the past five years to the numerator.
- Tobacco Use and Exposure Assessment: Added POV Z71.6 and CPT G9458 to tobacco screening and tobacco user definitions.
- Tobacco Cessation: (1) Added POV Z71.6 and CPT G9458 to tobacco screening and tobacco cessation counseling definition. (2) Added patient education with CPT G9016 to tobacco cessation counseling definition.
- Statin Therapy for the Prevention and Treatment of Cardiovascular Disease: (1) Removed lower age limit for patients with ASCVD. (2) Changed lower age limit to 20 for patients with LDL greater than or equal to (>=) 190. (3) Changed the time period for the denominator exclusion of rhabdomyolysis to be during the report period. (4) Updated the statin allergy denominator exception to statin-associated muscle symptoms or an allergy. (5) Removed the denominator exception for patients with LDL less than (<) 70. (6) Updated medication taxonomy BGP PQA STATIN MEDS.
Removed Dental Treatment measure from IPC report.

CRS VERSION 22.0

CRS Version 22.0 was released on March 2, 2022.

View the CRS 2022 (v22.0) National GPRA/GPRAMA Report Performance Measure List and Definitions [PDF - 754 MB]

View the CRS 2022 (v22.0) National GPRA Developmental Report Performance Measure List and Definitions [PDF - 1 MB]

Key enhancements included in CRS Version 22.0 are shown below.

Logic Changes to National GPRA/GPRAMA Report Measures

GPRA Developmental Measures:

Removed the following GPRA Developmental topics:

Colorectal Cancer Screening
Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

Updated codes and/or logic in the following measures: Adult Immunizations; Childhood Immunizations; Cancer Screening: Pap Smear Rates; Weight Assessment and Counseling for Nutrition and Physical Activity; Physical Activity Assessment; Appropriate Medication Therapy After a Heart Attack; HIV Screening; HIV Quality of Care; Sexually Transmitted Infection (STI) Screening; Proportion of Days Covered by Medication Therapy; Concurrent Use of Opioids and Benzodiazepines

Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes: (1) Added SNOMED subset PXRM BGP IPC HOSPICE to denominator exceptions. (2) Removed POV 412, I24.1, I25.2 from myocardial infarction definition. (3) Removed POV 272.0 from hypercholesterolemia definition. (4) Removed ICD-9 POVs from active liver disease definition. (5) Updated medication taxonomy BGP PQA STATIN MEDS.
Influenza: Added HCPCS codes Q2034-Q2039 to influenza definition.
Adult Immunizations: Added HCPCS codes Q2034-Q2039 to influenza definition.
Cancer Screening: Pap Smear Rates: Added LOINC codes 97156-4, 97157-2 to BGP HPV LOINC CODES taxonomy.
Colorectal Cancer Screening: Updated denominator age range to 45-75.
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease: (1) Added SNOMED subset PXRM BGP IPC HOSPICE to denominator exceptions. (2) Removed POV 412, I24.1, I25.2 from myocardial infarction definition. (3) Removed POV 272.0 from hypercholesterolemia definition. (4) Removed ICD-9 POVs from active liver disease definition. (5) Updated medication taxonomy BGP PQA STATIN MEDS.
HIV Screening: Added LOINC codes 97860-1, 97861-9 to BGP HIV TEST LOINC CODES taxonomy.

Removed the following topics from the Selected Measures Report: Medication Therapy for Persons with Asthma, Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly
Changed Baseline Year to 2016 from 2010.
Updated demo patients to include those with an SSN that begins with five zeros.